These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 19198839)

  • 1. Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4'-methanol-bisbenzonitrile in vitro.
    Jeong S; Woo MM; Flockhart DA; Desta Z
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):867-75. PubMed ID: 19198839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A.
    Jeong S; Nguyen PD; Desta Z
    Antimicrob Agents Chemother; 2009 Feb; 53(2):541-51. PubMed ID: 19029318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase.
    Grimm SW; Dyroff MC
    Drug Metab Dispos; 1997 May; 25(5):598-602. PubMed ID: 9152599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes.
    Murai K; Yamazaki H; Nakagawa K; Kawai R; Kamataki T
    Xenobiotica; 2009 Nov; 39(11):795-802. PubMed ID: 19845430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.
    Wen X; Wang JS; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2002 Jan; 57(11):799-804. PubMed ID: 11868802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19.
    Xu C; Desta Z
    Drug Metab Pharmacokinet; 2013; 28(4):362-71. PubMed ID: 23385314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes.
    Bae SH; Kwon MJ; Choi EJ; Zheng YF; Yoon KD; Liu KH; Bae SK
    Chem Biol Interact; 2013 Sep; 205(1):11-9. PubMed ID: 23777987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effects of memantine on human cytochrome P450 activities: prediction of in vivo drug interactions.
    Micuda S; Mundlova L; Anzenbacherova E; Anzenbacher P; Chladek J; Fuksa L; Martinkova J
    Eur J Clin Pharmacol; 2004 Oct; 60(8):583-9. PubMed ID: 15378224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro evaluation of the interaction potential of irosustat with drug-metabolizing enzymes.
    Ventura V; Solà J; Peraire C; Brée F; Obach R
    Drug Metab Dispos; 2012 Jul; 40(7):1268-78. PubMed ID: 22451700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivation of CYP2A6 by the Dietary Phenylpropanoid trans-Cinnamic Aldehyde (Cinnamaldehyde) and Estimation of Interactions with Nicotine and Letrozole.
    Chan J; Oshiro T; Thomas S; Higa A; Black S; Todorovic A; Elbarbry F; Harrelson JP
    Drug Metab Dispos; 2016 Apr; 44(4):534-43. PubMed ID: 26851241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene.
    Taavitsainen P; Juvonen R; Pelkonen O
    Drug Metab Dispos; 2001 Mar; 29(3):217-22. PubMed ID: 11181487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A.
    Desta Z; Soukhova NV; Flockhart DA
    Antimicrob Agents Chemother; 2001 Feb; 45(2):382-92. PubMed ID: 11158730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents.
    Lu WJ; Xu C; Pei Z; Mayhoub AS; Cushman M; Flockhart DA
    Breast Cancer Res Treat; 2012 May; 133(1):99-109. PubMed ID: 21814747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of cytochrome P450 enzymes involved in ketamine metabolism by use of liver microsomes and specific cytochrome P450 enzymes from horses, dogs, and humans.
    Mössner LD; Schmitz A; Theurillat R; Thormann W; Mevissen M
    Am J Vet Res; 2011 Nov; 72(11):1505-13. PubMed ID: 22023129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of green tea catechins on cytochrome P450 2B6, 2C8, 2C19, 2D6 and 3A activities in human liver and intestinal microsomes.
    Misaka S; Kawabe K; Onoue S; Werba JP; Giroli M; Tamaki S; Kan T; Kimura J; Watanabe H; Yamada S
    Drug Metab Pharmacokinet; 2013; 28(3):244-9. PubMed ID: 23268924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro.
    Zhang W; Kilicarslan T; Tyndale RF; Sellers EM
    Drug Metab Dispos; 2001 Jun; 29(6):897-902. PubMed ID: 11353760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical pharmacological evaluation of letrozole as a novel treatment for gliomas.
    Dave N; Chow LM; Gudelsky GA; LaSance K; Qi X; Desai PB
    Mol Cancer Ther; 2015 Apr; 14(4):857-64. PubMed ID: 25695958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer.
    Lisztwan J; Pornon A; Chen B; Chen S; Evans DB
    Breast Cancer Res; 2008; 10(4):R56. PubMed ID: 18611244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Establishment of an aromatase inhibitor letrozole-resistant breast cancer cell model].
    Chen HY; Liu ZH
    Zhonghua Zhong Liu Za Zhi; 2013 Jun; 35(6):423-8. PubMed ID: 24119901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A letrozole-based dual aromatase-sulphatase inhibitor with in vivo activity.
    Wood PM; Woo LW; Humphreys A; Chander SK; Purohit A; Reed MJ; Potter BV
    J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):123-30. PubMed ID: 15862957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.